Prevalence of multiple sclerosis in French farmers: a national survey, Multiple Sclerosis, vol.10, p.156, 2004. ,
Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy, Clinical Immunology, vol.142, issue.1, pp.15-24 ,
DOI : 10.1016/j.clim.2011.05.005
Gilenya®) encore un immunosuppresseur dans le sclérose en plaques, Rev Prescire, vol.31, issue.330, pp.249-254, 2011. ,
Article du 05 janvier, 2011. ,
Brochure d'information à l'usage des patients, 2004. ,
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.1-12, 2009. ,
DOI : 10.1136/ard.2009.126532
The ESPOIR cohort: A ten-year follow-up of early arthritis in France, Joint Bone Spine, vol.74, issue.5, pp.440-445, 2007. ,
DOI : 10.1016/j.jbspin.2007.06.001
Can we estimate the incidence, prevalence, and outcomes of rheumatoid arthritis in France?, Joint Bone Spine, vol.71, issue.2, pp.95-97, 2004. ,
DOI : 10.1016/j.jbspin.2003.10.005
The use of biological agents in the treatment of rheumatoid arthritis, Ann Acad Med Singapore, vol.36, pp.128-134, 2007. ,
Immunopathologie de la polyarthrite rhumatoïde, EMC-Rhumatologie Orthopédie, vol.2004, issue.1, pp.218-230 ,
DOI : 10.1016/j.emcrho.2004.03.003
The clinical features of rheumatoid arthritis, European Journal of Radiology, vol.27, issue.27, pp.18-24, 1998. ,
DOI : 10.1016/S0720-048X(98)00038-2
Interleukin-20 antagonist is a potential drug for rheumatoid arthritis, Arthritis Rheum, vol.54, issue.9, pp.2722-2733, 2006. ,
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry, Annals of the Rheumatic Diseases, vol.69, issue.2, pp.400-408, 2010. ,
DOI : 10.1136/ard.2009.117762
URL : https://hal.archives-ouvertes.fr/hal-00456934
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events, Annals of the Rheumatic Diseases, vol.68, issue.7, pp.1136-1145, 2009. ,
DOI : 10.1136/ard.2008.091025
Infliximab Expected to Receive Approval For the Treatment of Ulcerative Colitis, p.7, 2005. ,
Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochemical Journal, vol.374, issue.1 ,
DOI : 10.1042/bj20030407
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochemical Journal, vol.334, issue.2, pp.297-314, 1998. ,
DOI : 10.1042/bj3340297
Safety of biologic therapy in rheumatoid arthritis, Nature Reviews Rheumatology, vol.2011, issue.7, pp.639-652 ,
Prevalence of spondyloarthropathies in France: 2001, Annals of the Rheumatic Diseases, vol.64, issue.10, pp.1431-1435, 2001. ,
DOI : 10.1136/ard.2004.029207
Ankylosing spondylitis, The Lancet, vol.369, issue.9570, pp.1379-1390, 2007. ,
DOI : 10.1016/S0140-6736(07)60635-7
URL : https://hal.archives-ouvertes.fr/hal-00503871
Psoriatic arthritis as a distinct disease entity, Journal of Postgraduate Medicine, vol.53, issue.1, pp.63-71, 2007. ,
DOI : 10.4103/0022-3859.30334
Psoriatic arthritis, Best Practice & Research Clinical Rheumatology, vol.16, issue.4, pp.523-535, 2002. ,
DOI : 10.1016/S1521-6942(02)90248-2
Ankylosing spondylitis, The Lancet, vol.369, issue.9570, pp.1379-1390, 2007. ,
DOI : 10.1016/S0140-6736(07)60635-7
URL : https://hal.archives-ouvertes.fr/hal-00503871
Ankylosing Spondylitis: A Contemporary Perspective on Diagnosis and Treatment, Seminars in Arthritis and Rheumatism, vol.36, issue.4, pp.210-223, 2007. ,
DOI : 10.1016/j.semarthrit.2006.08.003
Pathogenesis of psoriatic arthritis, Current Opinion in Rheumatology, vol.16, issue.4, pp.338-343, 2004. ,
DOI : 10.1097/01.bor.0000129718.13939.81<
Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease, Journal of the European Academy of Dermatology and Venereology, vol.205, issue.Suppl. II, pp.9-13, 2009. ,
DOI : 10.1111/j.1468-3083.2009.03363.x
New insights into the pathogenesis and genetics of psoriatic arthritis, Nature Clinical Practice Rheumatology, vol.437, issue.2 ,
DOI : 10.1038/ncprheum0987
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection, Annals of the Rheumatic Diseases, vol.68, issue.6 ,
DOI : 10.1136/ard.2009.108233
New ASAS classification criteria for peripheral spondyloarthritis, ARD, vol.70, pp.25-31, 2011. ,
Certolizumab pegol, Nature Reviews Drug Discovery, vol.371, issue.8, pp.641-644, 2008. ,
DOI : 10.1038/nrd2654
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor: STUDY OF Lck- AND FynT-DEPENDENT T CELL ACTIVATION, Journal of Biological Chemistry, vol.271, issue.2, pp.695-701, 1996. ,
DOI : 10.1074/jbc.271.2.695
Discovery of JSI-124 (Cucurbitacin I), a selective janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice1, Cancer Research, vol.63, pp.1270-1279, 2003. ,
Treating inflammation with the Janus kinase inhibitor CP-690 ,
Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA), Arthritis Rheum, vol.60, issue.10, p.1924, 2009. ,
Implications dans la polyarthrite rhumatoïde, RéfleXions Rhumatologiques, vol.129, issue.14, 2010. ,
Mercator. 9 ème édition ,
URL : https://hal.archives-ouvertes.fr/hal-00494894
Choix stratégiques et concurrence, Economica, vol.426 ,
The Strategy Process; concepts, context, cases. 4 th Editions ,
Mobilizing invisible assets, 1987. ,
8 ème édition. Pearson Education, 2008. ,
Stratégies et structures de l'entreprise, Ed. d'Organisation, 2006. ,
Building Strategy from the middle, 2000. ,
Competitive Strategy, techniques for analyzing industries and competitors. The Free Press, 1980. ,
Barriers to new Competition, 1956. ,
DOI : 10.4159/harvard.9780674188037
Les outils de la stratégie ,
91 pages Sites Internet 11)http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about- ms/who-gets-ms/index.aspx. Consulté le 24)https://adpharm.net/blog/2011/03/rebif-delivered-through-innovation/ consulté le 23, 2008. ,